Figure 1.

Study design. MTX, methotrexate; TCZ, tocilizumab. (A) *Patients who did not achieve ≥20% improvement from baseline in swollen and tender joint counts at week 16 were offered escape therapy with open-label TCZ 8 mg/kg. ^†60 placebo+MTX and 65 TCZ+MTX patients completed 12 weeks. ^‡59 placebo+MTX and 65 TCZ+MTX patients completed 24 weeks. (B) *TCZ 8 mg/kg every 4 weeks+background MTX (7.5–25 mg weekly). ^†Escape therapy, open-label TCZ (8 mg/kg every 4 weeks+background MTX). ^‡Patients who received at least one dose of TCZ (double-blind or open-label).